Juuli Raivola

685 total citations
13 papers, 502 citations indexed

About

Juuli Raivola is a scholar working on Oncology, Molecular Biology and Genetics. According to data from OpenAlex, Juuli Raivola has authored 13 papers receiving a total of 502 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 7 papers in Molecular Biology and 4 papers in Genetics. Recurrent topics in Juuli Raivola's work include Cytokine Signaling Pathways and Interactions (6 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (4 papers) and Cancer Cells and Metastasis (2 papers). Juuli Raivola is often cited by papers focused on Cytokine Signaling Pathways and Interactions (6 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (4 papers) and Cancer Cells and Metastasis (2 papers). Juuli Raivola collaborates with scholars based in Finland, Sweden and Australia. Juuli Raivola's co-authors include Olli Silvennoinen, Anniina Virtanen, T. Haikarainen, Henrik M. Hammarén, Daniela Ungureanu, Hanna Karvonen, Astrid Murumägi, Mariliina Arjama, Harlan Barker and Markku Varjosalo and has published in prestigious journals such as Methods in enzymology on CD-ROM/Methods in enzymology, Cellular and Molecular Life Sciences and Nature Chemical Biology.

In The Last Decade

Juuli Raivola

12 papers receiving 488 citations

Peers

Countries citing papers authored by Juuli Raivola

Since Specialization

Citations

This map shows the geographic impact of Juuli Raivola's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Juuli Raivola with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Juuli Raivola more than expected).

Fields of papers citing papers by Juuli Raivola

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Juuli Raivola. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Juuli Raivola. The network helps show where Juuli Raivola may publish in the future.

Co-authorship network of co-authors of Juuli Raivola

This figure shows the co-authorship network connecting the top 25 collaborators of Juuli Raivola. A scholar is included among the top collaborators of Juuli Raivola based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Juuli Raivola. Juuli Raivola is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

#	Work	Indexed citations
1	ROR1-PI3K/AKT signaling drives adaptive resistance to cell cycle blockade in TP53 mutated ovarian cancer 2026 ·Cell Death and Disease ·Juuli Raivola, (unknown), (unknown), (unknown), Harlan Barker, (unknown), (unknown), (unknown), (unknown), (unknown), Astrid Murumägi, Daniela Ungureanu	0
2	A multiplex single-cell RNA-Seq pharmacotranscriptomics pipeline for drug discovery 2024 ·Nature Chemical Biology ·(unknown), Harlan Barker, (unknown), Sweta Sharma Saha, Juuli Raivola, Astrid Murumägi, Daniela Ungureanu	9
3	Molecular and functional profiling of primary normal ovarian cells defines insights into cancer development and drug responses 2024 ·PubMed ·(unknown), (unknown), (unknown), (unknown), Lassi Paavolainen, Harlan Barker, Juuli Raivola, Akira Hirasawa, Olli Kallioniemi, Astrid Murumägi, Daniela Ungureanu	1
4	ROR1-STAT3 signaling contributes to ovarian cancer intra-tumor heterogeneity 2023 ·Cell Death Discovery ·(unknown), (unknown), Juuli Raivola, Kari Salokas, Kaiyang Zhang, Markku Varjosalo, Teijo Pellinen, Katja Välimäki, (unknown), Synnöve Staff, Sampsa Hautaniemi, Astrid Murumägi, Daniela Ungureanu	10
5	Multiomics characterization implicates PTK7 in ovarian cancer EMT and cell plasticity and offers strategies for therapeutic intervention 2022 ·Cell Death and Disease ·Juuli Raivola, (unknown), Hanna Karvonen, (unknown), Kari Salokas, Wilhelmiina Niininen, (unknown), Kaiyang Zhang, Mariliina Arjama, (unknown), Brinton Seashore‐Ludlow, Markku Varjosalo, Olli Kallioniemi, Sampsa Hautaniemi, Astrid Murumägi, Daniela Ungureanu	17
6	Cellular thermal shift assay (CETSA) for determining the drug binding affinity using Ba/F3 clones stably expressing receptor pseudokinases 2022 ·Methods in enzymology on CD-ROM/Methods in enzymology ·Hanna Karvonen, Juuli Raivola, Daniela Ungureanu	5
7	New insights into the molecular mechanisms of ROR1, ROR2, and PTK7 signaling from the proteomics and pharmacological modulation of ROR1 interactome 2022 ·Cellular and Molecular Life Sciences ·Juuli Raivola, (unknown), Kari Salokas, Hanna Karvonen, Wilhelmiina Niininen, (unknown), Markku Varjosalo, Daniela Ungureanu	8
8	Evaluating Targeted Therapies in Ovarian Cancer Metabolism: Novel Role for PCSK9 and Second Generation mTOR Inhibitors 2021 ·Cancers ·(unknown), Juuli Raivola, Hanna Karvonen, Mariliina Arjama, Harlan Barker, Astrid Murumägi, Daniela Ungureanu	18
9	Janus Kinases in Leukemia 2021 ·Cancers ·Juuli Raivola, T. Haikarainen, (unknown), Olli Silvennoinen	35
10	Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases 2019 ·BioDrugs ·Anniina Virtanen, T. Haikarainen, Juuli Raivola, Olli Silvennoinen	204
11	Characterization of JAK1 Pseudokinase Domain in Cytokine Signaling 2019 ·Cancers ·Juuli Raivola, T. Haikarainen, Olli Silvennoinen	24
12	Hyperactivation of Oncogenic JAK3 Mutants Depend on ATP Binding to the Pseudokinase Domain 2018 ·Frontiers in Oncology ·Juuli Raivola, Henrik M. Hammarén, Anniina Virtanen, (unknown), Alister C. Ward, Olli Silvennoinen	15
13	The regulation of JAKs in cytokine signaling and its breakdown in disease 2018 ·Cytokine ·Henrik M. Hammarén, Anniina Virtanen, Juuli Raivola, Olli Silvennoinen	156

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact